FindTrial
Sign In

Comparison of Anticoagulant Effects Between Nafamostat Mesylate and Sodium Citrate in Double Filtration Plasmapheresis

Comparison of Anticoagulant Effects Between Nafamostat Mesylate and Sodium Citrate in Double Filtration Plasmapheresis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117445
Enrollment
Unknown
Registered
2026-01-23
Start date
2026-01-23
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure, kidney transplantation, ANCA-associated vasculitis, lupus nephritis

Interventions

Nafamostat mesilate:N/A
Sodium citrate :N/A

Sponsors

The First Affiliated Hospital of Army Medical University PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years; 2. Patients requiring DFPP therapy due to autoimmune diseases, toxic diseases, or transplant antibodies; 3. High bleeding risk (defined as: active bleeding, recent surgical history, coagulation disorder, or platelet count <50 × 10^9/L);

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Allergic to NM or RCA; 3. Severe hepatic impairment and hypoxemia; 4. Incomplete clinical records;

Design outcomes

Primary

MeasureTime frame
Incidence of blood clotting;Complications;—

Countries

China

Contacts

Public ContactZheng Honglian

The First Affiliated Hospital of Army Medical University PLA

878867731@qq.com+86 23 6876 5375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026